Skip to content
value.today
Vaccinex, Inc. logo

Vaccinex, Inc.

Total raised
$6 M
1 round on record
Latest round
$6 M
May 2017
First round on record
May 2017
Today
Went public
See the company page

Vaccinex, Inc. is listed today as Vaccinex, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Vaccinex, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$2 MPrivate placement after listingUnder $2 million

Vaccinex, Inc.: Private sale, Mar 2024

Investors in this round

1 investor had bought by the notice of Apr 12, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth Evans · Executive Officer
  • Ernest S. Smith, Ph.D. · Executive Officer
  • Jill Sanchez · Executive Officer
  • Maurice Zauderer, Ph.D. · Director, Executive Officer
  • Albert D. Friedberg · Director
  • Bala S. Manian, Ph.D. · Director
  • Barbara Yanni · Director
  • Chrystyna Bedrij Stecyk · Director
  • Gerald E. Van Strydonck · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total remaining to be sold represents the aggregate exercise price of warrants to purchase shares of the Company's common stock.”

Signed by Maurice Zauderer, Ph.D., President, CEO. Source: SEC Form D, newest notice filed Apr 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Mar 2024$1 MPrivate placement after listingUnder $2 million

Vaccinex, Inc.: Private sale, Mar 2024

Investors in this round

3 investors had bought by the notice of Apr 12, 2024: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth Evans · Executive Officer
  • Ernest S. Smith, Ph.D. · Executive Officer
  • Jill Sanchez · Executive Officer
  • Maurice Zauderer, Ph.D. · Director, Executive Officer
  • Albert D. Friedberg · Director
  • Bala S. Manian, Ph.D. · Director
  • Barbara Yanni · Director
  • Chrystyna Bedrij Stecyk · Director
  • Gerald E. Van Strydonck · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total remaining to be sold represents the aggregate exercise price of warrants to purchase shares of the Company's common stock.”

Signed by Maurice Zauderer, Ph.D., President, CEO. Source: SEC Form D, newest notice filed Apr 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Sep 2020$2 MPrivate placement after listing$2 to $10 million

Vaccinex, Inc.: Private sale, Sep 2020

Investors in this round

1 investor had bought by the notice of Sep 16, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ernest S. Smith · Executive Officer
  • Maurice Zauderer · Executive Officer, Director
  • Raymond E. Watkins · Executive Officer
  • Scott E. Royer · Executive Officer
  • Albert D. Friedberg · Director
  • Bala S. Manian · Director
  • Barbara E. Yannni · Director
  • Chrystyna D. Bedrij Stecyk · Director
  • Gerald E. Van Strydonck · Director
  • J. Jeffrey Goater · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Royer, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 16, 2020. Read the notice at the SEC.

equitySEC
Jul 2020$4 MPrivate placement after listing$2 to $10 million

Vaccinex, Inc.: Private sale, Jul 2020

Investors in this round

1 investor had bought by the notice of Jul 15, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ernest S. Smith · Executive Officer
  • Maurice Zauderer · Executive Officer, Director
  • Raymond E. Watkins · Executive Officer
  • Scott E. Royer · Executive Officer
  • Albert D. Friedberg · Director
  • Alejandro M. Berlin · Director
  • Bala S. Manian · Director
  • Barbara E. Yanni · Director
  • Chrystyna E. Bedrij Stecyk · Director
  • Gerald E. Van Strydonck · Director
  • J. Jeffrey Goater · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Royer, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 15, 2020. Read the notice at the SEC.

equitySEC
Jan 2020$7 MPrivate placement after listing$2 to $10 million

Vaccinex, Inc.: Private sale, Jan 2020

Investors in this round

5 investors had bought by the notice of Feb 3, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ernest S. Smith · Executive Officer
  • Maurice Zauderer · Executive Officer, Director
  • Raymond E. Watkins · Executive Officer
  • Scott E. Royer · Executive Officer
  • Albert D. Friedberg · Director
  • Alejandro M. Berlin · Director
  • Bala S. Manian · Director
  • Barbara E. Yanni · Director
  • Gerald E. Van Strydonck · Director
  • J. Jeffrey Goater · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Royer, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 3, 2020. Read the notice at the SEC.

equitySEC
Jul 2019$14 MPrivate placement after listing$10 to $50 million

Vaccinex, Inc.: Private sale, Jul 2019

Investors in this round

5 investors had bought by the notice of Aug 14, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ernest S. Smith · Executive Officer
  • Maurice Zauderer · Executive Officer, Director
  • Raymond E. Watkins · Executive Officer
  • Scott E. Royer · Executive Officer
  • Albert D. Friedberg · Director
  • Alejandro M. Berlin · Director
  • Bala S. Manian · Director
  • Barbara E. Yanni · Director
  • Gerald E. Van Strydonck · Director
  • J. Jeffrey Goater · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Royer, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 14, 2019. Read the notice at the SEC.

equitySEC
May 2017$6 MNo. 1$2 to $10 million

Vaccinex, Inc.: Raise no. 1, May 2017

Investors in this round

1 investor had bought by the notice of Jul 7, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Vaccinex, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $18 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ernest S. Smith · Executive Officer
  • John E. Leonard · Executive Officer
  • Maurice Zauderer · Executive Officer, Director
  • Raymond E. Watkins · Executive Officer
  • Steven P. Cobourn · Executive Officer
  • Alan L. Crane · Director
  • Albert D. Friedberg · Director
  • Alejandro M. Berlin · Director
  • Bala S. Manian · Director
  • Barbara E. Yanni · Director
  • Gerald E. Van Strydonck · Director
  • J. Jeffrey D. Goater · Director
  • Jacob B. Frieberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven P Cobourn, Cfo. Source: SEC Form D, newest notice filed Jul 7, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vaccinex, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Apr 2024).

    SEC Form D (revenue range) · Apr 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2024

Products and services#

No products or services of Vaccinex, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Vaccinex, Inc.
InvestorKindAmountRoundRoleSource
Antibody Investments LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
FCMI Parent Co.Othernot statednot statedHeld Series A, B, B1, B2 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vaccinex (Rochester), L.L.C.Othernot statednot statedHeld Series B and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vaccinex, Inc.
NameRoleNamed in
Elizabeth EvansExecutive officerApr 2024
Ernest S. Smith, Ph.D.Executive officerApr 2024
Jill SanchezExecutive officerApr 2024
Maurice Zauderer, Ph.D.Executive officerApr 2024
Ernest S. SmithExecutive officerSep 2020
Maurice ZaudererExecutive officerSep 2020
Raymond E. WatkinsExecutive officerSep 2020
Scott E. RoyerExecutive officerSep 2020
John E. LeonardExecutive officerJul 2017
Steven P. CobournExecutive officerJul 2017
Albert D. FriedbergDirectorApr 2024
Bala S. Manian, Ph.D.DirectorApr 2024
Barbara YanniDirectorApr 2024
Chrystyna Bedrij StecykDirectorApr 2024
Gerald E. Van StrydonckDirectorApr 2024
Jacob B. FriebergDirectorApr 2024
Maurice Zauderer, Ph.D.DirectorApr 2024
Bala S. ManianDirectorSep 2020
Barbara E. YannniDirectorSep 2020
Chrystyna D. Bedrij StecykDirectorSep 2020
J. Jeffrey GoaterDirectorSep 2020
Maurice ZaudererDirectorSep 2020
Alejandro M. BerlinDirectorJul 2020
Barbara E. YanniDirectorJul 2020
Chrystyna E. Bedrij StecykDirectorJul 2020
Alan L. CraneDirectorJul 2017
J. Jeffrey D. GoaterDirectorJul 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.